Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling. [PDF]
, 2015 In glioblastoma (GBM), the EGF receptor (EGFR) and Src family kinases (SFKs) contribute to an aggressive phenotype. EGFR may be targeted therapeutically; however, resistance to EGFR-targeting drugs such as Erlotinib and Gefitinib develops quickly.
Cavenee, WK +5 more
core
Genome-Wide Multiple Sclerosis Association Data and Coagulation [PDF]
, 2019 The emerging concept of a crosstalk between hemostasis, inflammation, and immune system prompt recent works on coagulation cascade in multiple sclerosis (MS).
Arianna Fornasiero +10 more
core +2 more sources
Regulation of Urokinase/Urokinase Receptor Interaction by Heparin-like Glycosaminoglycans [PDF]
Journal of Biological Chemistry, 2001 We show here that the interaction between the urokinase-type plasminogen activator and its receptor, which plays a critical role in cell invasion, is regulated by heparan sulfate present on the cell surface and in the extracellular matrix. Heparan sulfate oligomers showing a composition close to the dimeric repeats of heparin (glucosamine-NSO(3)(6-OSO ...
PUCCI, MARCO +3 more
openaire +4 more sources
Multi‐Module Micro/Nanorobots for Biomedical and Environmental Remediation Applications
Advanced Intelligent Systems, EarlyView.Multi‐module microrobots (MNRs) have overcome the limitations of single‐module systems by integrating components such as propeller, actuator, manipulator, and imaging modalities. They show promise in biomedical applications, such as targeted drug delivery and tissue repair, as well as in environmental remediation, including pollutant removal.
Bairong Zhu +4 more
wiley +1 more source
Immunocytochemical Phenotyping of Disseminated Tumor Cells in Bone Marrow by uPA Receptor and CK18: Investigation of Sensitivity and Specificity of an Immunogold/Alkaline Phosphatase Double Staining Protocol [PDF]
, 1997 Phenotyping of cytokeratin (CK) 18-positive cells in bone marrow is gaining increasing importance for future prognostic screening of carcinoma patients. Urokinase-type plasminogen activator receptor (uPA-R) is one example of a potential aggressive marker
Allgayer, Heike +5 more
core +1 more source
A Region in Domain II of the Urokinase Receptor Required for Urokinase Binding [PDF]
Journal of Biological Chemistry, 2000 The urokinase receptor is composed of three homologous domains based on disulfide spacing. The contribution of each domain to the binding and activation of single chain urokinase (scuPA) remains poorly understood. In the present paper we examined the role of domain II (DII) in these processes.
Bruce S. Sachais +8 more
openaire +2 more sources
Interdependence of kallikrein-related peptidases in proteolytic networks [PDF]
, 2010 Human kallikrein-related peptidases (KLKs) are 15 homologous serine proteases involved in several (patho)physiological processes, including cancer. Secreted as precursors, they are activated upon proteolytic release of a short propeptide. We searched for
Debela +21 more
core +1 more source
Role of Urokinase Receptor in Tumor Progression and Development
Theranostics, 2013 Elevated level of urokinase receptor (uPAR) is detected in various aggressive cancer types and is closely associated with poor prognosis of cancers. Binding of uPA to uPAR triggers the conversion of plasminogen to plasmin and the subsequent activation of
Hyangsoon Noh +2 more
semanticscholar +1 more source
Breaking barriers: Smart vaccine platforms for cancer immunomodulation
Cancer Communications, EarlyView.Abstract Despite significant advancements in cancer treatment, current therapies often fail to completely eradicate malignant cells. This shortfall underscores the urgent need to explore alternative approaches such as cancer vaccines. Leveraging the immune system's natural ability to target and kill cancer cells holds great therapeutic potential ...
Mohammad Mahmoudi Gomari +11 more
wiley +1 more source
Recent advances in cardiovascular medicines : thrombolytics [PDF]
, 1990 Thrombolytic therapy represents a major advance in reducing mortality following myocardial infarction. Pharmacists must be aware of the principles and problems of thrombolysis and the extant large studies conducted in hospitals and in the community. This
Felice, Herbert +2 more
core